LCN2 and acute kidney injury: Damage markers, such as NGAL and L-FABP, comprise the first generation of AKI biomarkers, which were developed during the past 20 years; however, because of specificity and sensitivity limitations, especially for patients with comorbid conditions, damage markers have been used mainly for research purposes [2].